In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.
The following faculty have disclosed:
Manesh R. Patel, MD, chair for this educational event, receives research funds from AstraZeneca, Bayer, Janssen, Mytonomy, and Procyrion; and receives consulting fees from Bayer, Janssen, and Novartis.
John H. Alexander, MD, MHS, faculty for this educational event, receives research funds from Artivion/CryoLife, Bayer, Bristol-Myers Squibb, CSL Behring, Ferring, U.S. FDA, Humacyte and US NIH; and receives consulting fees from AbbVie, Akros, Artivion/CryoLife, AtriCure, Bayer, Bristol-Myers Squibb, Ferring, GlaxoSmithKline, Janssen, Novostia, Pfizer, Portola, Theravance and Veralox.
Steve Deitelzweig, MD, MMM, SFHM, FACP, FACC, faculty for this educational event, receives research funds from BMS and Pfizer; and receives consulting fees from BMS, Pfizer and Bayer.
Christopher B. Granger, MD, faculty for this educational event, receives research grants or contracts from Alnylam Pharm., Boehringer Ingelheim, Bristol Myers Squibb, Duke Clinical Research Institute, FDA, Janssen Pharmaceutica Products, L.P., Lilly Pharmaceutical, Novartis Pharmaceutical Company, Pfizer, and Philips; receives consulting fees from Abbvie, Abiomed, Anthos., Bayer Corporation, Boehringer Ingelheim, Boston Scientific Corporation, Bristol Myers Squibb, Cardionomic, CeleCor Therapeutics, HengRui USA, Janssen Pharmaceutica Products, L.P., Medscape, LLC, Medtronic Inc., Merck, NephroSynergy, NIH, Novo Nordisk, Novartis Pharmaceutical Company, Pfizer, Philips, REATA, and Veralox Therapeutics, Inc; and has ownership interest in Tenac.io.
Tatjana Potpara, MD, PhD, FESC, faculty for this educational event, has no relevant financial relationships with ineligible companies.